课题基金 / 基金详情

Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention

Sustained Release Curcumin Microspheres for Breast Cancer Chemoprevention
缓释姜黄素微球用于乳腺癌化学预防
批准号:
7894676
负责人:
Jayanth Panyam
金额:
$7.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-16 至 2011-06-30

项目摘要

项目成果

Jayanth Panyam的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Curcumin, a naturally occurring dietary polyphenol, has shown significant potential as a chemopreventive in cell culture models of breast cancer. However, curcumin suffers from poor oral bioavailability in vivo, resulting in sub-optimal systemic exposure following oral administration. The inability to achieve effective plasma and tissue concentrations following oral administration is a critical problem, because this limits curcumin's potential as a chemopreventive in breast cancer. The long-term objective of this research is to develop a once-a-year depot formulation of dietary polyphenols like curcumin that could significantly lower the risk of developing breast cancer, especially in women at high risk of developing breast cancer (specific gene mutations, Her-2 amplification, etc). The objective of this R03 grant application is to develop advanced preliminary data regarding the chemopreventive efficacy of a polymeric sustained release curcumin formulation in a transgenic model of ErbB2-driven breast cancer. Our limited preliminary studies show that microspheres formulated from the biodegradable poly(D,L-lactide-co-glycolide) polymer can efficiently encapsulate curcumin and sustain its release in mouse over several weeks. The central hypothesis of this research is that increased and prolonged systemic availability of curcumin following subcutaneous administration of a sustained release microsphere formulation will result in effective chemoprevention. To test this hypothesis, two Specific Aims will be addressed. In Specific Aim 1, we will develop a microsphere formulation that releases curcumin over a 3-month period and determine the systemic exposure of curcumin following a single subcutaneous dose of the formulation. In addition, pharmacodynamics of curcumin will be determined by evaluating several chemoprevention biomarkers. In Specific Aim 2, we will investigate the chemopreventive efficacy of sustained release microspheres in the BALB-neuT model of breast cancer. ErbB2 expression, pre-malignant inflammation response in the mammary epithelium, and tumor multiplicity will be used as endpoints to establish the chemopreventive efficacy of curcumin microspheres. Collectively, these studies will help us in acquiring critical preliminary data regarding the chemopreventive efficacy of sustained release curcumin microspheres. If the proposed approach is successful, results of this research will suggest a novel chemoprevention modality for breast cancer.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Chemopreventive efficacy of oral curcumin: a prodrug hypothesis.
口服姜黄素的化学预防功效:前药假设。
DOI: 10.1096/fj.201900166r
发表时间: 2019
期刊: FASEB journal : official publication of the Federation of American Societies for Experimental Biology
影响因子: --
作者: [Liu,Garvey, Khanna,Vidhi, Kirtane,Ameya, Grill,Alex, Panyam,Jayanth]
通讯作者: Panyam,Jayanth
DOI: 10.1007/s13346-017-0377-4
发表时间: 2018-04
期刊: Drug delivery and translational research
影响因子: 5.4
作者: [Grill AE, Shahani K, Koniar B, Panyam J]
通讯作者: Panyam J
DOI: 10.1158/0008-5472.can-09-4362
发表时间: 2010-06-01
期刊: Cancer research
影响因子: 11.2
作者: [Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J]
通讯作者: Panyam J
DOI: 10.1007/s13346-014-0199-6
发表时间: 2014-08
期刊: DRUG DELIVERY AND TRANSLATIONAL RESEARCH
影响因子: 5.4
作者: [Grill, Alex E., Koniar, Brenda, Panyam, Jayanth]
通讯作者: Panyam, Jayanth
TLR7/8 agonist design and delivery for effective anticancer immune response
  • 批准号:
    10424571
  • 项目类别:
  • 资助金额:
    $35.23万
  • 财政年份:
    2021
  • 负责人:
    Jayanth Panyam
  • 依托单位:
TLR7/8 agonist design and delivery for effective anticancer immune response
  • 批准号:
    10643962
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2021
  • 负责人:
    Jayanth Panyam
  • 依托单位:
TLR7/8 agonist design and delivery for effective anticancer immune response
  • 批准号:
    10312341
  • 项目类别:
  • 资助金额:
    $37.41万
  • 财政年份:
    2021
  • 负责人:
    Jayanth Panyam
  • 依托单位:
TLR7/8 agonist design and delivery for effective anticancer immune response
  • 批准号:
    10947664
  • 项目类别:
  • 资助金额:
    $35.26万
  • 财政年份:
    2021
  • 负责人:
    Jayanth Panyam
  • 依托单位:
海外基金